GlassScriptPhysician profile
Kenny Tai
NPI 1447710272
$2,808.01
in general payments reported to CMS, 2019-2025
18 companies · $628 in 2025
The $628 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.83 · 2022: $729 · 2023: $765 · 2024: $673 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,881.97 |
| Education | $183.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $976.78 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $445.00 | 2023-2025 | Empaveli |
| Janssen Biotech, INC. | $362.71 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Daiichi Sankyo INC. | $190.33 | 2022-2025 | Injectafer, Vanflyta, Enhertu |
| Sanofi-Aventis U.S. LLC | $137.52 | 2022-2025 | |
| Incyte Corporation | $99.00 | 2022 | |
| Celgene Corporation | $94.37 | 2022-2023 | Pomalyst |
| Adaptive Biotechnologies Corporation | $87.11 | 2022 | |
| Pharmaessentia USA Corporation | $81.61 | 2025 | Besremi |
| Karyopharm Therapeutics INC. | $64.22 | 2022-2023 | Xpovio |
| Genzyme Corporation | $60.08 | 2022-2023 | |
| Amgen INC. | $52.30 | 2022 | |
| Alexion Pharmaceuticals, INC. | $48.31 | 2022-2024 | Ultomiris |
| Taiho Oncology, INC. | $26.94 | 2022 | |
| Legend Biotech USA INC. | $24.95 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.95 | 2024 | Xospata |
| Merck Sharp & Dohme LLC | $20.00 | 2025 | Prevymis, Zerbaxa |
| Kadmon Pharmaceuticals LLC | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenny Tai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.